The application for clinical trials, CTA, was submitted to the Norwegian Medicines Agency in August. Targovax has already received advice from EMA, the European Medicines Agency, for the clinical plans. TG01 will very soon be ready for Clinical Phase I/II, collaboration partner for the Clinical trial will be Oslo University Hospital, Radiumhospitalet.